Sumitomo Pharma (OTCMKTS:DNPUF) Rating Lowered to Neutral at Citigroup

Sumitomo Pharma (OTCMKTS:DNPUFGet Rating) was downgraded by investment analysts at Citigroup from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Monday, The Fly reports.

Shares of Sumitomo Pharma stock opened at $9.69 on Monday. Sumitomo Pharma has a 52 week low of $8.58 and a 52 week high of $20.20. The firm’s 50 day moving average is $9.71 and its two-hundred day moving average is $11.14.

About Sumitomo Pharma (Get Rating)

Sumitomo Pharma Co, Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia.

Read More

The Fly logo

Receive News & Ratings for Sumitomo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sumitomo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.